Asymptomatic  	Asymptomatic  	 JJ	B-NP
primary  	primary  	 JJ	I-NP
hyperparathyroidism 	hyperparathyroidism 	 NN	I-NP
:  	:  	 :	O
surgical  	surgical  	 JJ	O
and  	and  	 CC	O
medical  	medical  	 JJ	B-NP
management  	management  	 NN	I-NP
Primary  	Primary  	 JJ	I-NP
hyperparathyroidism  	hyperparathyroidism  	 NNS	I-NP
( 	( 	 -LRB-	O
PHPT 	PHPT 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
a  	a  	 DT	O
common  	common  	 JJ	O
endocrine  	endocrine  	 JJ	B-NP
disorder 	disorder 	 NN	I-NP
,  	,  	 ,	O
frequently  	frequently  	 RB	O
asymptomatic 	asymptomatic 	 VBN	O
.  	.  	 .	O
Notwithstanding 	Notwithstanding 	 RB	O
,  	,  	 ,	O
mild  	mild  	 JJ	O
PHPT  	PHPT  	 NNP	B-NP
may  	may  	 MD	O
cause  	cause  	 VB	O
adverse  	adverse  	 JJ	O
skeletal  	skeletal  	 JJ	B-NP
effects  	effects  	 NNS	I-NP
that  	that  	 WDT	O
include  	include  	 VBP	O
high  	high  	 JJ	O
bone  	bone  	 NN	O
remodeling 	remodeling 	 NN	O
,  	,  	 ,	O
reduced  	reduced  	 VBN	B-NP
bone  	bone  	 NN	I-NP
mineral  	mineral  	 NN	I-NP
density  	density  	 NNS	I-NP
( 	( 	 -LRB-	O
BMD 	BMD 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
increased  	increased  	 VBD	B-NP
fracture  	fracture  	 JJ	I-NP
risk 	risk 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
definitive  	definitive  	 JJ	O
therapy  	therapy  	 NN	O
for  	for  	 IN	O
symptomatic  	symptomatic  	 NN	O
and  	and  	 CC	O
asymptomatic  	asymptomatic  	 JJ	B-NP
PHPT  	PHPT  	 NNP	I-NP
( 	( 	 -LRB-	O
aPHPT 	aPHPT 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
parathyroidectomy 	parathyroidectomy 	 VBN	O
,  	,  	 ,	O
which  	which  	 WDT	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
shown  	shown  	 VBN	O
to  	to  	 TO	O
increase  	increase  	 VB	O
BMD 	BMD 	 NNP	B-NP
.  	.  	 .	O
In  	In  	 IN	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
choose  	choose  	 VBP	O
not  	not  	 RB	O
to  	to  	 TO	O
be  	be  	 VB	O
treated  	treated  	 VBN	O
surgically  	surgically  	 NNS	O
or  	or  	 CC	O
have  	have  	 VBP	O
contraindications  	contraindications  	 VBN	O
for  	for  	 IN	O
surgery 	surgery 	 NN	O
,  	,  	 ,	O
medical  	medical  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
should  	should  	 MD	O
include  	include  	 VB	O
drugs  	drugs  	 NNS	O
designed  	designed  	 VBN	O
to  	to  	 TO	O
protect  	protect  	 VB	O
the  	the  	 DT	O
skeleton  	skeleton  	 NN	O
and 	and 	 CC	O
/ 	/ 	 NNP	O
or  	or  	 CC	O
to  	to  	 TO	O
lower  	lower  	 VB	O
serum  	serum  	 JJ	B-NP
calcium 	calcium 	 NN	I-NP
,  	,  	 ,	O
such  	such  	 JJ	O
as  	as  	 IN	O
bisphosphonates 	bisphosphonates 	 NN	B-NP
,  	,  	 ,	O
hormone  	hormone  	 JJ	B-NP
replacement 	replacement 	 NN	I-NP
,  	,  	 ,	O
and 	and 	 CC	O
/ 	/ 	 NNP	O
or  	or  	 CC	O
calcimimetic  	calcimimetic  	 JJ	B-NP
agents 	agents 	 NNS	I-NP
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
there  	there  	 EX	O
are  	are  	 VBP	O
currently  	currently  	 RB	O
no  	no  	 DT	O
fracture  	fracture  	 JJ	O
data  	data  	 NNS	O
for  	for  	 IN	O
any  	any  	 DT	O
of  	of  	 IN	O
these  	these  	 DT	O
options 	options 	 NNS	O
.  	.  	 .	O
Obviously 	Obviously 	 RB	O
,  	,  	 ,	O
there  	there  	 EX	O
is  	is  	 VBZ	O
the  	the  	 DT	O
need  	need  	 NN	O
for  	for  	 IN	O
larger  	larger  	 JJR	O
randomized  	randomized  	 NNS	O
controlled  	controlled  	 VBN	B-NP
trials  	trials  	 NNS	I-NP
with  	with  	 IN	O
fractures  	fractures  	 NN	O
as  	as  	 IN	O
end-points  	end-points  	 JJ	B-NP
to  	to  	 TO	O
evaluate  	evaluate  	 VB	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
medical  	medical  	 JJ	B-NP
treatment 	treatment 	 NN	I-NP
.  	.  	 .	O
